Baker McKenzie, Cooley Build $2B Bayer-Vividion Deal
Bayer will pay up to $2 billion for Vividion Therapeutics, which focuses on cancers and inflammatory diseases that don't currently have drug-based treatments, the companies said Thursday, in a transaction stitched...To view the full article, register now.
Already a subscriber? Click here to view full article